| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Pres., R&D, And CMO | Chief Medical Officer, EVP R&D
1 company
Taub Rebecca is a Director at MDGL. Recent filings cover 0 purchases and 90 sales.
Our model assigns Taub Rebecca a below-average insider score of 36/100, based on 14 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -46.1%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sell | 491 | $431.94 | $212,082.54 | -0.1% | +11.1% | - | |
| Jan 9, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE | 18,410 | $522.40 | $9,617,312.08 | -3.9% | +2.0% | - | |
| Jan 9, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE | 240 | $550.33 | $132,080.00 | - | +2.0% | - | |
| Dec 10, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE | 18,650 | $552.15 | $10,297,572.90 | -3.9% | -21.7% | - | |
| Aug 12, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE | 46,463 | $355.32 | $16,509,031.65 | -9.2% | +38.1% | - | |
| Jul 18, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE | 1,000 | $350.01 | $350,005.00 | -0.2% | +32.3% | +65.6% | |
| Jul 17, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE | 29,101 | $353.19 | $10,278,098.16 | -5.9% | +24.3% | +58.7% | |
| Jan 24, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Pres., R&D, And CMO | Sell | 648 | $335.24 | $217,235.52 | -0.1% | -2.5% | +46.4% | |
| Jan 17, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Pres., R&D, And CMO | Sell | 1,689 | $273.41 | $461,789.49 | -0.4% | +2.7% | +70.8% | |
| Apr 8, 2024 | MDGL Madrigal Pharmaceuticals, Inc. | Pres., R&D, And CMO | Sale+OE | 2,676 | $245.99 | $658,257.61 | -0.6% | +16.9% | +21.8% |